Autobio Diagnostics Co EV/FCF

Mitä Autobio Diagnostics Co tekee? Autobio Diagnostics Co Ltd, listed on the Shanghai Stock Exchange under ticker 603658.SS, is a healthcare company based in Zhengzhou, China. The company specializes in the research, development, manufacturing, integration, service, and distribution of in vitro diagnostic reagents and instruments. With a workforce of 5,505 employees, Autobio Diagnostics went public on September 1, 2016. Its product portfolio includes immunodiagnostic reagents such as microplate chemiluminescence diagnostic reagents, enzyme-linked immunosorbent assay (ELISA) diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. The company also offers microbiology detection products, including training detection reagents, susceptibility detection reagents, and rapid detection reagents. Device products encompass microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers. Autobio Diagnostics primarily serves domestic markets within China, focusing on providing diagnostic solutions for healthcare applications. The company's headquarters is located in Zhengzhou, Henan Province, and it operates within the healthcare sector, specifically in the health care industry. Its website, https://www.autobio.com.cn/, provides further information on its services and products. Autobio Diagnostics Co on yksi Eurpooliin suosituimmista yhtiöistä.